B cell maturation antigen (BCMA) is a target for various immunotherapies and a biomarker
for tumor load in multiple myeloma (MM). We report a case of irreversible BCMA loss in a …

Deciphering Multiple Myeloma evolution in the whole bone marrow is key to inform curative
strategies. Here, we perform spatial-longitudinal whole-exome sequencing, including 140 …

To elucidate the mechanisms underlying relapse from chemotherapy in multiple myeloma,
we performed a longitudinal study of 33 patients entered into Total Therapy protocols …

Bispecific T cell engagers (TCEs) have shown promise in the treatment of various cancers,
but the immunological mechanism and molecular determinants of primary and acquired …

18 F-Fluorodeoxyglucose (FDG)–positron emission tomography (PET) and diffusion-weighted
magnetic resonance imaging with background signal suppression (DWIBS) are 2 …

To identify risk variants for multiple myeloma, we conducted a genome-wide association study
of 1,675 individuals with multiple myeloma and 5,903 control subjects. We identified risk …

Multiple myeloma (MM) is a plasma cell malignancy with a significant heritable basis.
Genome-wide association studies have transformed our understanding of MM predisposition, but …

Virtually all patients with multiple myeloma become unresponsive to treatment over time.
Relapsed/refractory multiple myeloma (RRMM) is accompanied by the clonal evolution of …

To identify variants for multiple myeloma risk, we conducted a genome-wide association
study with validation in additional series totaling 4,692 individuals with multiple myeloma (cases…

Background Anti-CD38 monoclonal antibodies have consistently shown increased efficacy
when added to standard of care for patients with multiple myeloma. We aimed to assess the …